Kinaset Therapeutics Kinaset Therapeutics Kinaset Therapeutics

Kinaset Therapeutics

Treatments for respiratory diseases

Kinaset Therapeutics develops novel therapeutics that positively impact people affected by intractable diseases, including severe asthma. Asthma is a complex and heterogeneous disease affecting over 300 million people worldwide, with approximately 10% of patients having severe asthma suffering from frequent exacerbations, compromised lung function, and a reduced quality of life. The company will start a phase 2 clinical trial in 2024.
 

Investment 
details

Staff

5

Location

USA

Our goal is to build Kinaset into a leading respiratory therapeutics company focused on patients starting with KN-002.

Robert Clarke

CEO

Header Kinaset
Partnership Gimv Partnership Gimv Partnership Gimv

Partnership Gimv

The best-in-class profile and tailor-made dry powder formulation captured Gimv’s interest from the early start. Together with this very experienced and dedicated management team, Gimv is convinced KN-002 can make a real difference to severe asthma patients who have limited treatment options today.

Deal Team

Portret Bram Vanparys
Bram
Vanparys*

Managing Partner - Head Life Sciences

Belgium
Portret Rishabh Chawla
Rishabh
Chawla

Senior Associate

Belgium